Monitoring symptoms in cancer patients using remote technology
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia (AML) Using Remote Symptom Monitoring
This study is trying to see how remote technology can help track symptoms in cancer patients with breast, lung, ovarian cancer, multiple myeloma, or acute myelogenous leukemia during their treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 25 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Carevive Systems, Inc. Industry-sponsored |
| Locations | 7 sites (New Haven, Connecticut and 6 other locations) |
| Trial ID | NCT05974150 on ClinicalTrials.gov |
What this trial studies
This observational study aims to gather real-world clinical and patient-reported data from cancer patients diagnosed with breast, lung, ovarian cancer, multiple myeloma, or acute myelogenous leukemia. Participants will complete a baseline survey and then engage in weekly electronic patient-reported outcome surveys for a minimum of 12 weeks using the Carevive platform. The data collected will contribute to a registry that enhances understanding of patient experiences during active treatment. The study utilizes an electronic care planning system to facilitate remote symptom monitoring.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with a diagnosis of breast, lung, ovarian cancer, multiple myeloma, or acute myelogenous leukemia who can complete online surveys.
Not a fit: Patients who cannot understand English or are unable to complete online surveys will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the management of symptoms in cancer patients by providing valuable insights into their treatment experiences.
How similar studies have performed: Other studies utilizing remote symptom monitoring have shown promise in improving patient outcomes, suggesting this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All participants must be 18 years of age or older. * Subjects may be any stage and anywhere in the treatment continuum. * Subject participants must have a diagnosis of a breast, lung, AML, ovarian cancer or multiple myeloma. * Subjects must be able to complete on-line surveys using a cell phone, tablet, or computer. * All participants must be able to understand English. Exclusion Criteria: * Any patient who cannot understand written or spoken English. * Any patient without the ability to complete on-line surveys using a cell phone, tablet, or computer. * Any patient on a treatment clinical trial. * Any prisoner and/or other vulnerable persons as defined by NIH (45 CFR 46, Subpart B, C and D).
Where this trial is running
New Haven, Connecticut and 6 other locations
- Yale Cancer Center — New Haven, Connecticut, United States (Completed)
- Northshore University Health System — Evanston, Illinois, United States (Recruiting)
- Univeristy of North Carolina at Chapel Hill — Chapel Hill, North Carolina, United States (Completed)
- Duke — Durham, North Carolina, United States (Completed)
- Cleveland Clinic Mercy Hospital — Canton, Ohio, United States (Recruiting)
- University Hospitals Seidman Cancer Center — Cleveland, Ohio, United States (Recruiting)
- Tri-County Hematology & Oncology Associates, Inc. — Massillon, Ohio, United States (Recruiting)
Study contacts
- Study coordinator: Julie Scott, Msn
- Email: Julie.Scott@Carevive.com
- Phone: 8778423210
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.